STOCK TITAN
  1. Home
  2. News
  3. RNA

Avidity Biosciences Inc - RNA STOCK NEWS

Welcome to our dedicated news page for Avidity Biosciences (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Avidity Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avidity Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avidity Biosciences's position in the market.

News
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Avidity Biosciences, Inc. announces inducement grants under Nasdaq Listing Rule 5635(c)(4) to three new non-executive employees. The grants include 37,500 stock options and 18,750 restricted stock units, with an exercise price of $22.73 per share. The options and RSUs will vest over four years and are subject to employment conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Avidity Biosciences to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) announced participation in upcoming conferences to discuss RNA therapeutics. Cantor Fitzgerald Virtual Muscular Dystrophy Symposium on April 3 and 23rd Annual Needham Virtual Healthcare Conference on April 10 will feature Avidity management. Live webcasts and event details will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
conferences
-
News
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) granted non-qualified stock options and restricted stock units to new non-executive employees under the 2022 Inducement Plan. The options have an exercise price of $24.24 per share and will vest over four years, while the RSUs will vest in four equal installments on the first four anniversaries of the applicable vesting commencement date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
none
News
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) accelerates Phase 3 HARBOR study for del-desiran in DM1 patients after positive long-term data from MARINA-OLE trial. Del-desiran showed reversal of disease progression in myotonic dystrophy type 1 patients, with improvements in vHOT, muscle strength, and daily activities. Avidity to host investor event on March 4, 2024, to discuss the findings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.22%
Tags
clinical trial
-
News
Avidity Biosciences Honors Rare Disease Day®
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) supports Rare Disease Day, emphasizing the importance of awareness for rare diseases. Avidity is dedicated to developing RNA therapeutics for rare muscle diseases. The company has three rare disease programs in clinical development: DM1, DMD44, and FSHD. Rare Disease Day aims to raise awareness globally and advocate for breakthrough therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.92%
Tags
none
-
News
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) secures funding from various investors and plans to raise $400 million through a private placement. The company expects its cash reserves to last until late 2026. AOC 1001 data from MARINA-OLE™ will be presented at an investor event on March 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.92%
Tags
none
News
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) reported financial results for Q4 2023 and highlighted progress. They plan to initiate the global Phase 3 HARBOR™ trial for AOC 1001 for DM1, share data from clinical programs for FSHD and DMD44, and advance cardiology and skeletal muscle programs. Avidity is in a strong financial position with $595 million at the end of 2023 and a cash runway through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.92%
Tags
earnings
-
News
Avidity Biosciences to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) announces participation in upcoming healthcare conferences to discuss RNA therapeutics. The company will be present at TD Cowen 44th Annual Health Care Conference, Leerink Partners 2024 Global Biopharma Conference, and Barclays 26th Annual Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
conferences
-
News
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) granted stock options and RSUs to new non-executive employees under the 2022 Inducement Plan. The options have an exercise price of $13.98 per share and will vest over four years, while the RSUs will vest in four equal installments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
News
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
Rhea-AI Summary
Avidity Biosciences Receives Rare Pediatric Disease Designation from FDA for AOC 1044 in Duchenne Muscular Dystrophy Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
Stock RNA logo
Avidity Biosciences Inc

Nasdaq:RNA

RNA Rankings

#1875 Ranked by Market Cap
#5049 Ranked by Stock Gains
N/A Ranked by Dividends

RNA Stock Data

1.92B
67.97M
6.41%
85.5%
12.52%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About RNA

avidity biosciences is pioneering a new class of precision medicines – antibody-sirna conjugates (asc™) – to deliver nucleic acid therapeutics against genetic drivers of disease. our ascs have drug-like properties similar to antibodies and antibody-drug conjugates. importantly, their unique sirna-based “payloads” permit selective targeting of disease-associated mrnas against virtually any target of interest. our leadership includes seasoned scientists and executives with deep expertise in the fields of antibody conjugation, chemistry, formulations, oligonucleotide therapeutics, drug delivery and cancer biology. our employees are high energy, creative people who are passionate about solving hard problems and bringing new drugs to patients. we strive to work with partners to discover best-in-class molecules with the goal of long-term, joint value creation. we have also attracted support from top-tier investors including f-prime capital, ecor1 capital, brace pharma and other sophisticated